Cancer Journal

•  
• Overview
•  
• Identity
•  
• View All
•  

Overview

publication venue for

• Fractionated stereotactic radiotherapy for acoustic neuroma 2007
• Outcome of partial hepatectomy for large (> 10 cm) hepatocellular carcinoma 2005
• Prospective evaluation of a novel approach for the use of a quantitative galactose oxidase–Schiff reaction in ductal fluid samples from women with breast carcinoma 2004
• Pathophysiologic interactions in skeletal metastasis 2000
• The effects of radiation therapy on quality of life of women with breast carcinoma 2000
• Pleomorphic xanthoastrocytoma 1999
• Blood lipid profiles in children with acute lymphoblastic leukemia 1998
• Interstitial fluid pressure in cervical carcinoma 1998
• Assessment of cytologic follow-up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions 1998
• Self-reported comprehensive health status of adult brain tumor patients using the Health Utilities Index 1997
• The incidence of pancreatic cancer in women with a BRCA1 or BRCA2 mutation. 2024
• Metabolic, cardiac, and bone health testing in patients with prostate cancer on androgen-deprivation therapy: A population-based assessment of adherence to therapeutic monitoring guidelines. 2024
• Curing pediatric cancer: A global view. Examples from acute lymphoblastic leukemia.  130:2247-2252. 2024
• Development of EPAT: An assessment tool for pediatric hematology/oncology training programs.  129:3448-3456. 2023
• The protective role of postoperative radiation therapy in low and intermediate grade major salivary gland malignancies: A study of the Canadian Head and Neck Collaborative Research Initiative.  129:3263-3274. 2023
• Impact of bortezomib‐based versus lenalidomide maintenance therapy on outcomes of patients with high‐risk multiple myeloma.  129:2179-2191. 2023
• The risks of cancer in older women with BRCA pathogenic variants: How far have we come?.  129:901-907. 2023
• Impact of autologous transplantation on survival in patients with newly diagnosed multiple myeloma who have high‐risk cytogenetics: A meta‐analysis of randomized controlled trials.  128:2288-2297. 2022
• Fatigue and endocrine symptoms among women with early breast cancer randomized to endocrine versus chemoendocrine therapy: Results from the TAILORx patient‐reported outcomes substudy.  128:536-546. 2022
• An evaluation of memory and attention in BRCA mutation carriers using an online cognitive assessment tool.  127:3183-3193. 2021
• Maximizing cancer prevention through genetic navigation for Lynch syndrome detection in women with newly diagnosed endometrial and nonserous/nonmucinous epithelial ovarian cancer.  127:3082-3091. 2021
• Erratum to: “A system for classifying cancers diagnosed in adolescents and young adults”.  127:3035-3040. 2021
• Examining the ability of the Cancer and Aging Research Group tool to predict toxicity in older men receiving chemotherapy or androgen‐receptor–targeted therapy for metastatic castration‐resistant prostate cancer.  127:2587-2594. 2021
• The challenges of delivering cost‐effective and affordable care to children with cancer in the developing world.  127:676-678. 2021
• Development and validation of a Surgical Prioritization and Ranking Tool and Navigation Aid for Head and Neck Cancer (SPARTAN‐HN) in a scarce resource setting: Response to the COVID‐19 pandemic.  126:4895-4904. 2020
• Performance characteristics of screening strategies to identify Lynch syndrome in women with ovarian cancer.  126:4886-4894. 2020
• A system for classifying cancers diagnosed in adolescents and young adults.  126:4634-4659. 2020
• How to reduce the impact of cervical cancer worldwide: Gaps and priority areas identified through the essential cancer and primary care packages: An analysis of effective interventions.  126:4697-4705. 2020
• Equal access to health care reduces racial disparities in prostate cancer outcomes.  126:4256-4257. 2020
• High triple‐negative breast cancer prevalence and aggressive prognostic factors in Barbadian women with breast cancer.  126:2217-2224. 2020
• Value assessment of oncology drugs using a weighted criterion‐based approach.  126:1530-1540. 2020
• Methodological rigor lacking in an analysis of acute myeloid leukemia incidence and geographic distribution in Canada.  126:1355-1356. 2020
• Wage losses among spouses of women with nonmetastatic breast cancer.  126:1124-1134. 2020
• Prostate cancer in young men: An emerging young adult and older adolescent challenge.  126:46-57. 2020
• Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancer.  125:1459-1469. 2019
• Leveraging patient‐reported outcomes data to inform oncology clinical decision making: Introducing the FACE‐Q Head and Neck Cancer Module.  125:863-872. 2019
• Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.  124:2115-2124. 2018
• Body composition in long‐term survivors of acute lymphoblastic leukemia diagnosed in childhood and adolescence: A focus on sarcopenic obesity.  124:1225-1231. 2018
• Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: A report from the International Radiosurgery Oncology Consortium for Kidney (IROCK).  124:934-942. 2018
• Adjuvant radiation therapy, androgen deprivation, and docetaxel for high‐risk prostate cancer postprostatectomy: Results of NRG Oncology/RTOG study 0621.  123:2489-2496. 2017
• Osteoporosis therapy and outcomes for postmenopausal patients with hormone receptor–positive breast cancer: NCIC CTG MA.27.  123:2444-2451. 2017
• Association between lymph node yield and survival among patients undergoing radical nephroureterectomy for urothelial carcinoma of the upper tract.  123:1741-1750. 2017
• Comparison of cancer survival trends in the United States of adolescents and young adults with those in children and older adults.  122:1009-1016. 2016
• Incidence and incidence trends of the most frequent cancers in adolescent and young adult Americans, including “nonmalignant/noninvasive” tumors.  122:1000-1008. 2016
• Thyroid cancer patient perceptions of radioactive iodine treatment choice: Follow‐up from a decision‐aid randomized trial.  121:3717-3726. 2015
• Preliminary patient‐reported outcomes analysis of 3‐dimensional radiation therapy versus intensity‐modulated radiation therapy on the high‐dose arm of the Radiation Therapy Oncology Group (RTOG) 0126 prostate cancer trial.  121:2422-2430. 2015
• Performance characteristics of screening strategies for Lynch syndrome in unselected women with newly diagnosed endometrial cancer who have undergone universal germline mutation testing.  120:3932-3939. 2014
• Genomic testing in cancer: Patient knowledge, attitudes, and expectations.  120:3066-3073. 2014
• Inferior survival among Aboriginal children with cancer in Ontario.  120:2751-2759. 2014
• Insurance status and distant‐stage disease at diagnosis among adolescent and young adult patients with cancer aged 15 to 39 years: National Cancer Data Base, 2004 through 2010.  120:1212-1219. 2014
• Impact of hemochromatosis gene mutations on cardiac status in doxorubicin‐treated survivors of childhood high‐risk leukemia.  119:3555-3562. 2013
• Outcome of children treated for relapsed acute lymphoblastic leukemia in Central America.  119:1277-1283. 2013
• Phase 2 results from Radiation Therapy Oncology Group Study 0537.  118:4244-4252. 2012
• Erratum: Stereotactic body radiotherapy for colorectal liver metastases.  118:2776-2776. 2012
• Follow‐up after chemoradiation for cervical cancer: Why?.  117:3875-3878. 2011
• Retracted: Up‐regulation of microRNA‐145 promotes differentiation by repressing OCT4 in human endometrial adenocarcinoma cells.  117:3989-3998. 2011
• Stereotactic body radiotherapy for colorectal liver metastases.  117:4060-4069. 2011
• The association between radiographic response and overall survival in men with metastatic castration‐resistant prostate cancer receiving chemotherapy.  117:3963-3971. 2011
• Supplementation with fish oil increases first-line chemotherapy efficacy in patients with advanced nonsmall cell lung cancer.  117:3774-3780. 2011
• Active therapy and models of care for adolescents and young adults with cancer.  117:2316-2322. 2011
• Adolescents, young adults, and cancer—the international challenge.  117:2245-2249. 2011
• Outcomes and metrics.  117:2342-2350. 2011
• Palliative care in adolescents and young adults with cancer.  117:2323-2328. 2011
• Preamble.  117:2239-2240. 2011
• Treatment of cancer in adolescents and young adults.  117:2258-2261. 2011
• Diabetes and breast cancer among women with BRCA1 and BRCA2 mutations.  117:1812-1818. 2011
• Nutritional intervention with fish oil provides a benefit over standard of care for weight and skeletal muscle mass in patients with nonsmall cell lung cancer receiving chemotherapy.  117:1775-1782. 2011
• CK8/18 expression, the basal phenotype, and family history in identifying BRCA1‐associated breast cancer in the Ontario site of the Breast Cancer Family Registry.  117:1350-1359. 2011
• Expectant management versus immediate treatment for low‐grade cervical intraepithelial neoplasia.  117:1438-1445. 2011
• Conservative and dietary interventions for cancer‐related lymphedema.  117:1136-1148. 2011
• Zoledronic acid use in cancer patients.  117:11-23. 2011
• Patient satisfaction with postmastectomy breast reconstruction.  116:5584-5591. 2010
• Symptom burden and performance status in a population‐based cohort of ambulatory cancer patients.  116:5767-5776. 2010
• Nurses provide valuable proxy assessment of the health‐related quality of life of children with Hodgkin disease.  116:1602-1607. 2010
• Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America.  116:1272-1280. 2010
• Bone and soft tissue sarcomas are often curable—But at what cost?.  115:4046-4054. 2009
• Developing quality indicators for cancer end‐of‐life care.  115:3820-3829. 2009
• Reliability of staging, prognosis, and comorbidity data collection in the National Comprehensive Cancer Network (NCCN) non‐Hodgkin lymphoma (NHL) multicenter outcomes database.  113:3209-3212. 2008
• Perceived family history risk and symptomatic diagnosis of prostate cancer.  113:2180-2187. 2008
• A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma.  113:573-581. 2008
• A systematic meta‐analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft‐tissue sarcoma.  113:573-581. 2008
• Normalization of bone markers is associated with improved survival in patients with bone metastases from solid tumors and elevated bone resorption receiving zoledronic acid.  113:193-201. 2008
• Outcome of patients who develop acute leukemia or myelodysplasia as a second malignancy after solid tumors treated surgically or with strategies that include chemotherapy and/or radiation.  112:1513-1521. 2008
• Passive smoking and the use of noncigarette tobacco products in association with risk for pancreatic cancer.  112:671-672. 2008
• Anticoagulation for the initial treatment of venous thromboembolism in patients with cancer: a systematic review.  113:1685-1694. 2008
• Thromboprophylaxis for patients with cancer and central venous catheters: a systematic review and a meta-analysis.  112:2483-2492. 2008
• Thromboprophylaxis for patients with cancer and central venous cathetersWithin the past 5 years, Dr. Schunemann received research grants, fees, and/or honoraria that were deposited into research accounts or received by a research group that he belongs to from AstraZeneca, Amgen, Chiesi Foundation, Lily, Pfizer, Roche, and UnitedBioSource for development or consulting regarding quality-of-life instruments for chronic respiratory diseases or as lecture fees related to the methodology of evidence-based practice guideline development and/or research methodology. Institutions or organizations with which that he is affiliated likely receive funding from for-profit sponsors that are supporting infrastructure and research that may serve his work. Based on a Cochrane Review first published in the Cochrane Library 2007, Issue 3. Cochrane Reviews are updated regularly as new evidence emerges and in response to comments and criticisms, and the Cochrane Library should be consulted for the most recent version of the review..  112:2483-2483. 2008
• Features at presentation predict children with acute lymphoblastic leukemia at low risk for tumor lysis syndrome.  110:1832-1839. 2007
• Expanded phase II trial of gemcitabine and capecitabine for advanced biliary cancer.  110:1307-1312. 2007
• Effectiveness of sperm banking in adolescents and young adults with cancer.  110:1125-1129. 2007
• Hidden barriers between knowledge and behavior.  109:1599-1606. 2007
• Osteopenia and cancer in children and adolescents.  109:1420-1431. 2007
• Intraperitoneal chemotherapy in the first‐line treatment of women with stage III epithelial ovarian cancer.  109:692-702. 2007
• Preface.  107:1643-1644. 2006
• Proceedings of a workshop.  107:1656-1658. 2006
• Chemoprevention: Drug pricing and mortality.  107:950-958. 2006
• Classification schemes for tumors diagnosed in adolescents and young adults.  106:1425-1430. 2006
• Breast carcinoma during pregnancy.  106:237-246. 2006
• Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction.  103:1996-2005. 2005
• Interobserver agreement in the interpretation of anal intraepithelial neoplasia.  103:1447-1456. 2005
• Systematic review of adjuvant care for women with Stage I ovarian carcinoma.  101:1926-1935. 2004
• Gemcitabine, dexamethasone, and cisplatin in patients with recurrent or refractory aggressive histology B‐cell non‐Hodgkin lymphoma.  101:1835-1842. 2004
• Adapting the Lung Cancer Symptom Scale (LCSS) to mesothelioma.  101:587-595. 2004
• Children, cancer, and nutrition—A dynamic triangle in review.  100:677-687. 2004
• Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion.  100:36-43. 2004
• Patterns of initial disease recurrence after resection of gallbladder carcinoma and hilar cholangiocarcinoma.  98:1689-1700. 2003
• Candidemia in women with breast carcinoma treated with high‐dose chemotherapy and autologous bone marrow transplantation.  98:24-30. 2003
• Impact of germline BRCA1 mutations and overexpression of p53 on prognosis and response to treatment following breast carcinoma.  97:527-536. 2003
• Chemotherapy with gemcitabine‐containing regimens for locally recurrent or metastatic nasopharyngeal carcinoma.  95:2516-2523. 2002
• Ethical communication in clinical trials.  95:2414-2421. 2002
• Factors that influence the recruitment of patients to Phase III studies in oncology.  95:1584-1591. 2002
• Plasma osteopontin.  95:506-512. 2002
• Phase II study of pemetrexed disodium, a multitargeted antifolate, and cisplatin as first-line therapy in patients with advanced nonsmall cell lung carcinoma.  92:595-600. 2001
• A comparison of four treatment strategies for ductal carcinoma in situ using decision analysis.  92:23-29. 2001
• Clinical utility, factor analysis, and further validation of the memorial delirium assessment scale in patients with advanced cancer.  88:2859-2867. 2000
• Pleuropulmonary blastoma.  88:2853-2858. 2000
• The effects of radiation therapy on quality of life of women with breast carcinoma.  88:2260-2266. 2000
• Splenic rupture in children with hematologic malignancies.  88:480-490. 2000
• Oral bisphosphonates.  88:6-14. 2000
• Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma (mycosis fungoides and the S�zary syndrome).  85:1985-1995. 1999
• Total skin electron radiation for patients with erythrodermic cutaneous T-cell lymphoma(mycosis fungoides and the Sézary syndrome).  85:1985-1995. 1999
• Induction failure in acute lymphoblastic leukemia of childhood.  85:1395-1404. 1999
• Evaluation of a patient file folder to improve the dissemination of written information materials for cancer patients.  83:1620-1625. 1998
• Blood lipid profiles in children with acute lymphoblastic leukemia.  83:379-384. 1998
• Author reply.  82:995-996. 1998
• Self-reported comprehensive health status of adult brain tumor patients using the health utilities index.  82:995-995. 1998
• Assessment of cytologic follow‐up as the recommended management for patients with atypical squamous cells of undetermined significance or low grade squamous intraepithelial lesions.  84:5-10. 1998
• The supportive care needs of newly diagnosed cancer patients attending a regional cancer center.  80:1518-1524. 1997
• Self‐reported comprehensive health status of adult brain tumor patients using the Health Utilities Index.  80:258-265. 1997
• The frequency and clinical course of cognitive impairment in patients with terminal cancer.  79:835-842. 1997
• Association of pleomorphic xanthoastrocytoma with cortical dysplasia and neuronal tumors: A report of three cases.  78:2551-2563. 1996
• A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis.  78:1470-1476. 1996
• Morphologic alterations in esophageal squamous cell carcinoma after preoperative high dose rate intraluminal brachytherapy.  77:2200-2205. 1996
• Errata: (Cancer (1996) 77 (2200-5)).  78:1524. 1996
• Mutant p53 protein overexpression is associated with poor outcome in patients with well or moderately differentiated ovarian carcinoma.  75:1327-1338. 1995
• Primary intracranial pleomorphic angioleiomyoma—A New Morphologic Variant. An immunohistochemical and electron microscopic study.  74:1915-1920. 1994
• Establishment and characterization of four human epithelial ovarian carcinoma cell lines.  74:900-906. 1994
• Pathologic findings from the national surgical adjuvant breast project protocol B-06 10-year pathologic and clinical prognostic discriminants.  71:2507-2514. 1993
• Hodgkin's disease in children 4 years of age or younger.  69:601-601. 1992
• Psychosocial adjustment in women with breast cancer.  67:1097-1117. 1991
• Addition of verapamil and tamoxifen to the initial chemotherapy of small cell lung cancer a phase I/II study.  65:1895-1902. 1990
• Well-differentiated papillary mesothelioma of the peritoneum. A clinicopathologic study of 22 cases.  65:292-296. 1990
• Radiation therapy in lymphomatoid granulomatosis.  64:821-824. 1989
• Changes in rat and human pepsinogen phenotypes induced by N′-methyl-N′nitro-n-nitrosoguanidine.  62:1958-1961. 1988
• Risk factors for varicella zoster disseminated infection among adult cancer patients with localized zoster.  62:1641-1646. 1988
• Observer variation in the pathologic diagnosis of malignant lymphoma in Canada.  62:314-318. 1988
• Neurologic disorders in patients with small cell lung cancer.  60:2275-2283. 1987
• Superior vena caval obstruction syndrome in small cell lung cancer.  57:847-851. 1986
• Pleural effusion in breast cancer. Thoracoscopy for hormone receptor determination.  57:324-327. 1986
• The natural-killer-cell-associated HNK-1 (Leu-7) antibody reacts with hypertrophic and malignant prostatic epithelium.  56:289-293. 1985
• The effect of intravenous hyperalimentation on the dietary intake of patients with small cell lung cancer. A randomized trial.  55:1572-1578. 1985
• Adenocarcinoma of the rectum metastatic to the oral cavity. Two cases and a review of the literature.  54:1110-1112. 1984
• Radionuclide angiography and endomyocardial biopsy in the assessment of doxorubicin cardiotoxicity.  53:1667-1674. 1984
• VP-16 alone and in combination with cisplatin in previously treated patients with small cell lung cancer.  53:1461-1466. 1984
• Acute lymphoblastic leukemia possible origin from a mediastinal germ cell tumor.  53:441-444. 1984
• Cytologic diagnosis of hepatocellular carcinoma by fine-needle aspiration biopsy.  53:547-552. 1984
• Serum folate and vitamin B12 levels in patients with small cell lung cancer.  53:306-310. 1984
• Chemotherapy for metastatic transitional carcinoma of the urinary tract:A prospective trial of methotrexate, adriamycin, and cyclophosphamide (MAC) with cis-platinum for failure.  51:216-219. 1983
• Chemotherapy of advanced ovarian carcinoma: Initial experience using a platinum-based combination.  49:1778-1783. 1982
• Malignant carcinoid tumors in children.  49:802-811. 1982
• Effect of high-dose thymidine infusions in patients with mycosis fungoides.  48:1513-1516. 1981
• Guided percutaneous fine-needle aspiration biopsy of the liver.  47:1781-1785. 1981
• Combination chemotherapy in invasive thymoma role of COPP..  46:1523-1527. 1980
• Radiation nephritis following combined abdominal radiation and chemotherapy (bleomycin-vinblastine).  41:2162-2164. 1978
• Specialized nutritional support in the cancer patient: Is it worthwhile?.  41:2359-2363. 1978
• An approach to immunotherapy using antibody to IgE in mast cell leukemia.  37:693-696. 1976

has subject area

• 1112 Oncology and Carcinogenesis (FoR)
• 1117 Public Health and Health Services (FoR)
• Oncology & Carcinogenesis (Science Metrix)

Identity

International Standard Serial Number (ISSN)

• 0008-543X

Electronic International Standard Serial Number (EISSN)

• 1097-0142